Download presentation
Presentation is loading. Please wait.
Published byAri-Matti Ketonen Modified over 6 years ago
1
360-Degree Perspectives on Biosimilars in Oncology
4
Definition of Biosimilars
5
History of Biosimilars Development
6
Why the Need for Oncology Biosimilars?
7
Biosimilars Are Not the Same as Generics
8
Biosimilars and Drift
9
Patent Expirations of Oncology Agents
10
State of Biosimilar Oncology Development
11
Regulatory Requirements for Oncology Biosimilars
12
Oncology Biosimilar Clinical Studies: Endpoints
13
Extrapolation of Indications
14
Interchangeability of Biosimilars
15
Naming of Biosimilar Products
16
Supportive Care Biosimilar: Filgrastim
17
Therapeutic Oncology Biosimilars: Trastuzumab
18
Therapeutic Oncology Biosimilars: Bevacizumab and Rituximab
19
Postmarketing Safety
20
Summary and Conclusions
21
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.